SRI TO 13 - CONTINUOUS RODENT AND NON-RODENT PHARMACOKINETIC ASSESSMENTS

NIH蓝图神经治疗网络(BPN)有一系列合作药物 由Lead Development运营的专注于神经系统疾病的发现和开发项目 团队(LDT)。这些项目将通过以下迭代过程开发治疗线索 药物化学优化及体内外试验。这一过程的一个组成部分将是 进行化合物的体内药代动力学(PK)评估。承包商应进行 啮齿动物和非啮齿动物PK研究评估血液和组织(主要是脑)的水平 由BPN提供的化合物，以支持BPN下的药物化学优化工作。 该任务顺序将涵盖啮齿动物(例如老鼠和小鼠)和非啮齿动物(例如狗、非人灵长类动物(NHP)、兔子)在未来五(5)年内每年对BPN倡议产生的测试品进行的PK研究。由于在给定的一年内需要进行的PK研究的实际数量不能提前准确地预测，因此最多可以讨价还价的是承包商在本任务单的五年期间每年进行大约6个啮齿动物和2个非啮齿动物药代动力学研究所需的人员和工作水平。人们认识到，在给定的一年中，PK研究的实际数量和这些研究中的任务类型可能会根据被评估的计划和测试项目的需求而变化。 为了制定提案，假设每年进行以下数量和类型的研究： ·六(6)项大鼠药代动力学研究 ·一(1)次单剂犬药代动力学研究 ·一(1)次单剂NHP药代动力学研究

The NIH Blueprint Neurotherapeutics Network (BPN) has a series of collaborative drug discovery and development projects focused on nervous system disorders, run by Lead Development Teams (LDTs). These projects will be developing therapeutic leads through an iterative process of medicinal chemistry optimization and in vitro and in vivo testing. A component of this process will be the conduct of in vivo pharmacokinetic (PK) assessment of compounds. The contractor shall conduct rodent and non-rodent PK studies to assess blood and tissue (primarily brain) levels of a novel compound supplied by the BPN to support medicinal chemistry optimization efforts under the BPN. This task order will cover the performance of rodent (e.g., rat and mouse) and non-rodent (e.g., dog, non-human primate (NHP), rabbit) PK studies of test articles generated by the BPN Initiative, on a yearly basis, for the next five (5) years. Since the actual number of PK studies that will be needed within a given year cannot be accurately predicted in advance, the most that can be fairly bargained for is for the Contractor to have available the personnel and level of effort associated with performing approximately 6 rodent and 2 non-rodent pharmacokinetic studies per year during the five-year period of this task order. It is recognized that the actual number of PK studies and types of tasks within these studies, in a given year, may vary based on the needs of the program and test article being assessed. For the purposes of proposal development, assume the following number and types of studies for each year: • Six (6) rat pharmacokinetic studies • One (1) single dose dog pharmacokinetic study • One (1) single dose NHP pharmacokinetic study